Interval_report_of_a_phase_I-II_study_utilizing_multiple_modalities_in_the_treatment_of_invasive_bladder_cancer._A_bladder-sparing_trial._Clinicians_at_the_Massachusetts_General_Hospital_have_used_two_cycles_of_methotrexate,_cisplatin,_and_vinblastine_(MCV)_before_radiotherapy_and_cisplatin_in_53_patients_with_muscle-invasive_bladder_cancer._Eleven_patients_did_not_complete_the_protocol,_but_overall,_the_toxicity_was_not_formidable._Of_the_total_patients_accessioned,_34_are_alive._Of_the_34_patients_in_the_series_who_completed_the_full_treatment_protocol,_the_estimated_survival_rate_at_54_months_is_77%._This_interim_analysis_suggests_that_the_treatment_is_achieving_at_least_limited_success_in_saving_lives_and_bladders.